PCL in Complete Response: Dealing with Maintenance Therapy and Protecting Your Mental Health image

PCL in Complete Response: Dealing with Maintenance Therapy and Protecting Your Mental Health

Oct 26, 2022
02:00PM - 03:00PM EDT
Online Event
Overview

Plasma cell leukemia patients who find themselves in complete response may still find challenges with maintenance therapy side effects. It may also hard to adjust to this new phase of survivorship as you might feel mentally and emotionally that a inevitable relapse is right around the corner. Join us to hear authentic experiences and advice as we support and share with one another.

Agenda
02:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speakers Paul Kleutghen.
02:05 PM
Presentation
Paul Kleutghen
Paul shares his experience with the challenges of maintenance therapy side effects.
02:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Paul Kleutghen

Paul Kleutghen

I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and a grandson who is the ‘light of my life’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs and, very specifically, CAR-T therapies, with recent contributions posted by Health affairs, the Institute for Clinical and Economic Review and the Centers for Medicare and Medicaid Services.